MX2022015601A - Compuesto para el tratamiento de infecciones coronavirales. - Google Patents

Compuesto para el tratamiento de infecciones coronavirales.

Info

Publication number
MX2022015601A
MX2022015601A MX2022015601A MX2022015601A MX2022015601A MX 2022015601 A MX2022015601 A MX 2022015601A MX 2022015601 A MX2022015601 A MX 2022015601A MX 2022015601 A MX2022015601 A MX 2022015601A MX 2022015601 A MX2022015601 A MX 2022015601A
Authority
MX
Mexico
Prior art keywords
treatment
compound
coronaviral
infections
coronaviral infections
Prior art date
Application number
MX2022015601A
Other languages
English (en)
Inventor
Ulrich Schubert
Wolfgang Brysch
Wegerer Jörg Von
Astrid Kaiser
Petra Schulz
Sara Schumann
Christian Setz
Original Assignee
Metriopharm Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from EP20000366.3A external-priority patent/EP3981405A1/en
Application filed by Metriopharm Ag filed Critical Metriopharm Ag
Publication of MX2022015601A publication Critical patent/MX2022015601A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D237/00—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings
    • C07D237/26—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings condensed with carbocyclic rings or ring systems
    • C07D237/30—Phthalazines
    • C07D237/32—Phthalazines with oxygen atoms directly attached to carbon atoms of the nitrogen-containing ring
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50—Pyridazines; Hydrogenated pyridazines
    • A61K31/502—Pyridazines; Hydrogenated pyridazines ortho- or peri-condensed with carbocyclic ring systems, e.g. cinnoline, phthalazine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0043—Nose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A61K9/006—Oral mucosa, e.g. mucoadhesive forms, sublingual droplets; Buccal patches or films; Buccal sprays
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Virology (AREA)
  • Organic Chemistry (AREA)
  • Oncology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Communicable Diseases (AREA)
  • Molecular Biology (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Otolaryngology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

La presente solicitud se refiere al uso de una ftalazindiona en la prevención o el tratamiento de infecciones coronavirales. Se divulgan composiciones farmacéuticas, combinaciones y técnicas de formulación ventajosas.
MX2022015601A 2020-06-10 2021-06-09 Compuesto para el tratamiento de infecciones coronavirales. MX2022015601A (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP20000212 2020-06-10
EP20000366.3A EP3981405A1 (en) 2020-10-08 2020-10-08 Compound for the treatment of coronaviral infections
PCT/EP2021/000071 WO2021249667A1 (en) 2020-06-10 2021-06-09 Compound for the treatment of coronaviral infections

Publications (1)

Publication Number Publication Date
MX2022015601A true MX2022015601A (es) 2023-01-30

Family

ID=76444360

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2022015601A MX2022015601A (es) 2020-06-10 2021-06-09 Compuesto para el tratamiento de infecciones coronavirales.

Country Status (11)

Country Link
US (1) US20230218614A1 (es)
EP (1) EP4164651A1 (es)
JP (1) JP2023529022A (es)
KR (1) KR20230027150A (es)
CN (1) CN116075306A (es)
AU (1) AU2021288757A1 (es)
BR (1) BR112022025134A2 (es)
CA (1) CA3182022A1 (es)
IL (1) IL298899A (es)
MX (1) MX2022015601A (es)
WO (1) WO2021249667A1 (es)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20240075029A1 (en) * 2020-12-02 2024-03-07 Metriopharm Ag Luminol for the prophylaxis and the treatment of sequelae of a sars-cov-2 infection
EP4193994A1 (en) * 2021-12-08 2023-06-14 MetrioPharm AG Combination of 5-amino-2,3-dihydro-1,4-phtalazinedione and a 6'-methoxycinchonan-9-ol for use in the treatment of coronaviral infections
EP4209219A1 (en) * 2022-01-07 2023-07-12 MetrioPharm AG Combination of budesonide and 5-amino-2,3-dihydro-1,4-phtalazinedione
WO2023131579A1 (en) * 2022-01-07 2023-07-13 Metriopharm Ag Use of 5-amino-2,3-dihydro-1,4-phthalazinedione in the treatment of congenital muscular dystrophies

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9011833D0 (en) 1990-05-25 1990-07-18 Collins Mary K L Inhibition of viral infection
US6953799B1 (en) 2002-10-30 2005-10-11 Bach Pharma, Inc. Modulation of cell fates and activities by diketo phthalazines
US7326690B2 (en) * 2002-10-30 2008-02-05 Bach Pharma, Inc. Modulation of cell fates and activities by phthalazinediones
ITMI20052036A1 (it) 2005-10-26 2007-04-27 Professional Dietetics Srl Composizioni farmaceutiche oftalmiche a base di amminoacidi e sodio ialuronato
PL231885B1 (pl) 2009-01-16 2019-04-30 Abidopharma Spolka Z Ograniczona Odpowiedzialnoscia Sposób wytwarzania soli 5-amino-2,3-dihydroftalazyno-1,4-di onu z metalami alkalicznymi, ich kompozycje farmaceutyczne i ich zastosowanie
CA2791327C (en) 2010-03-01 2018-10-30 Metriopharm Ag Crystalline forms of 5-amino-2,3-dihydrophthalazine-1,4-dione sodium salt, pharmaceutical preparations containing the same, method for production of said forms and use of said forms for modulating the immune system
EP2688565A1 (en) 2011-03-23 2014-01-29 Semorex Technologies Ltd. Treatment of proliferative disorders with a chemiluminescent agent
JP2017537958A (ja) * 2014-12-18 2017-12-21 メトリオファーム アーゲー ５−アミノ−２，３−ジヒドロフタラジン１，４−ジオンナトリウム塩の結晶形態、同一物を含む医薬製剤、及びこの形態の製造ための方法
CA3011767C (en) 2016-02-16 2024-02-06 Metriopharm Ag Crystalline form of 5-amino-2,3-dihydrophthalazine-1,4-dione
ES2796476T3 (es) * 2016-02-16 2020-11-27 Metriopharm Ag Procedimiento para la producción de una forma cristalina de 5-amino-2,3-dihidroftalazina-1,4-diona
EP3248602A1 (en) * 2016-05-26 2017-11-29 MetrioPharm AG Use of 5-amino-2,3-dihydro-1,4-phthalazinedione in the treatment of inflammatory and/or degenerative disorders of the tendons, ligaments of the joints, articular capsules and bursae
WO2018082814A1 (en) 2016-11-07 2018-05-11 Metriopharm Ag Use of 5-amino-2,3-dihydro-1,4-phthalazinedione in the treatment of chronic progressive multiple sclerosis
EP4125802A1 (en) * 2020-03-25 2023-02-08 MetrioPharm AG 5-amino-2,3-dihydro-1,4-phthalazinedione for treatment of acute lung injury
RU2747467C1 (ru) * 2020-07-17 2021-05-05 Муса Тажудинович Абидов Способ защиты от коронавирусной инфекции

Also Published As

Publication number Publication date
CN116075306A (zh) 2023-05-05
EP4164651A1 (en) 2023-04-19
WO2021249667A1 (en) 2021-12-16
US20230218614A1 (en) 2023-07-13
AU2021288757A1 (en) 2023-02-02
IL298899A (en) 2023-02-01
JP2023529022A (ja) 2023-07-06
BR112022025134A2 (pt) 2022-12-27
CA3182022A1 (en) 2021-12-16
KR20230027150A (ko) 2023-02-27

Similar Documents

Publication Publication Date Title
MX2022015601A (es) Compuesto para el tratamiento de infecciones coronavirales.
CR20220082A (es) N4-hidroxicitidina y derivados y usos antivirales relacionados con los mismos
MX2022015272A (es) Inhibidores de la proteina kras g12c y usos de estos.
UY37952A (es) Formulaciones de un inhibidor de la quinasa trk macrocíclica
JOP20180025B1 (ar) مشتقات اندولين مستبدلة بصفتها مانعات للتكاثر الفيروسي لحمى الفنك
MY197785A (en) Combinations of lsd1 inhibitors for the treatment of hematological malignancies
MX2021010106A (es) Inhibidores de la via de respuesta al estres integrada.
WO2018143552A3 (ko) 탈모방지 또는 발모촉진용 주사용 조성물
EP4342473A3 (en) Compounds useful in hiv therapy
EP4272832A3 (en) Antimicrobial compounds, compositions, and uses thereof
SG11201908234WA (en) Pharmaceutical composition comprising compound capable of penetrating blood-brain barrier as effective ingredient for preventing or treating brain cancer
WO2021046315A3 (en) Inhibitors of encephalitic alphaviruses
CR20230164A (es) Compuestos fosfolípidos y usos de estos
EP4234021A3 (en) Pharmaceutical composition comprising an adenosine derivative for use in the prevention or treatment of diabetic nephropathy
MX2020008360A (es) Forma cristalina de bictegravir sodico.
WO2021219244A8 (en) 6'-methoxycinchonan-9-ols for the treatment of coronaviral infections
MX2022005388A (es) Compuestos de pirrolidina y piperidina.
MX2022006940A (es) Composiciones farmaceuticas.
WO2018094023A3 (en) Cyclic dipeptides and wound healing
MX2022000433A (es) Proteinas de fusion a toxina para el tratamiento de enfermedades relacionadas con infecciones por cmv.
MX2018012210A (es) Glucono delta-lactona para el tratamiento de infecciones fungicas vaginales.
WO2022020353A3 (en) Methods and compositions for treatment and prevention of coronavirus infection
MX2022012001A (es) Tratamiento preventivo de la migra?a.
MX2023003087A (es) Compuesto de pirimido pirimidinona y composicion farmaceutica que comprenden el mismo.
MX2018010707A (es) Métodos y composiciones para el tratamiento de la infección por el virus del zika.